Danish pharmaceutical company Novo Nordisk is set to expand its existing production facilities to create additional product capacity in Kalundborg, Denmark.

The company will make an investment of more than DKr42bn this year for the expansion project, which seeks to expand Nova's current and upcoming line of products to treat major chronic diseases.

This investment will increase Nova's capacity throughout its entire global value chain, from active pharmaceutical ingredients (API) manufacture to packaging, with a significant portion investing in API capacity.

The expanded API facility will be spread across an area of 170,000m² and will be constructed as a multiproduct facility that can meet future processes and include advanced technology.

Novo Product Supply and Quality & IT executive vice-president Henrik Wulff said: “The significant investment announced today confirms the importance of utilising our existing sites, including in Denmark, as cornerstones for not only the growth we see but also to expand as fast as possible by utilising all the infrastructure, knowledge, and competences we already have.

“Our continued investment in global capacity demonstrates the belief we have in our current and future product portfolio and its relevance for people living with serious chronic diseases.”

Construction works are set to be completed in stages from the end of 2025 and be finalised in 2029.

Once Nova's projects are finished and its facilities are fully operational, it is projected that 800 new permanent jobs will be created. Meanwhile, up to 3,000 external workers are set to be hired throughout the construction phase.